June 17, 2020, 2:11 p.m. EDT

Companion Diagnostic Market Global Insights and Trends 2020 to 2026 | Roche Holding AG, Agilent Technologies Inc, Qiagen NV Abbott Laboratories, Inc

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Agilent Technologies Inc. (A)
  • X
    Qiagen N.V. (QGEN)
  • X
    Danaher Corp. (DHR)

or Cancel Already have a watchlist? Log In

Jun 17, 2020 (Market Insight Reports) -- Global Companion Diagnostic Market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this increasing sector. Readers will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.

According to the study, the Global Companion Diagnostics Market was valued at USD 2.98 Billion in 2018 and is projected to reach USD 9.51 Billion by 2026, growing at a CAGR of 15.59 % from 2019 to 2026.

Get Sample Copy of Companion Diagnostic Market Report –

https://www.marketinsightsreports.com/reports/06102084967/global-companion-diagnostic-market/inquiry/?Source=MW&mode=10

Key Players:

Roche Holding AG (swx:RO), Agilent Technologies Inc /zigman2/quotes/207081878/composite A -0.25% , Qiagen NV /zigman2/quotes/204869908/composite QGEN +4.73% , Abbott Laboratories, Inc., Almac Group, Danaher Corporation /zigman2/quotes/210555154/composite DHR -0.73% , Illumina Inc., Biomrieux SA, Myriad Genetics, Inc., and Sysmex Corporation, request sample for a complete list of companies.

The leading players of the industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among players will help the industry aspirants in planning their strategies.

Summary

Companion diagnostic will continue to increase in some applications to disease areas. The commercial success of drugs depends on the companion diagnostic. The increasing burden of disease and economic incentives for drug development are the two primary factors driving growth. Companion diagnostics reduces development time and Rx development costs and results in more favorable reimbursement by illustrating comparative effectiveness. In collaboration with pharmaceutical companies, the market is undergoing a remarkable change by developing and identifying the diagnostics to target patients. Approval and commercialization of any drug are challenging, before preferring any medicine or drug to humans it experiments on the animal to analyses its productive or positive as well as negative effects which further helps the researcher whether the drug is suitable for a disorder and human use. However, increasing development costs is restraining the growth of the market.

Market Segmentation:

BY PRODUCT & SERVICE (Assay Kits and Reagents, Software & Services) BY TECHNOLOGY (Polymerase Chain Reaction Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing, Other) BY INDICATION (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Gastric Cancer, Other) BY END USER (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories, Other)

Browse full report@

https://www.marketinsightsreports.com/reports/06102084967/global-companion-diagnostic-market?Source=MW&mode=10

Market Segment by Regions:

North America (the United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)

These segments are thoroughly evaluated on an individual basis and a team of analysts has ensured to give a crystal clear idea about various lucrative segments of the industry. This detailed analysis using segmentation by providing precise results on industry-related markets.

The report also analyzed the evolution of industry trends. Several macroeconomic factors such as Gross domestic product (GDP) and the increasing inflation rate is expected to affect directly or indirectly in the development of the industry.

Frequently Asked Questions about "Companion Diagnostic market" :

/zigman2/quotes/207081878/composite
US : U.S.: NYSE
$ 96.90
-0.24 -0.25%
Volume: 685,702
Aug. 11, 2020 3:31p
P/E Ratio
44.47
Dividend Yield
0.74%
Market Cap
$29.99 billion
Rev. per Employee
$336,959
loading...
/zigman2/quotes/204869908/composite
US : U.S.: NYSE
$ 48.65
+2.20 +4.73%
Volume: 1.64M
Aug. 11, 2020 3:30p
P/E Ratio
1,211
Dividend Yield
N/A
Market Cap
$10.60 billion
Rev. per Employee
$303,281
loading...
/zigman2/quotes/210555154/composite
US : U.S.: NYSE
$ 200.57
-1.49 -0.73%
Volume: 1.66M
Aug. 11, 2020 3:30p
P/E Ratio
49.40
Dividend Yield
0.36%
Market Cap
$143.34 billion
Rev. per Employee
$280,183
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.